No­var­tis li­cens­es two car­dio­vas­cu­lar RNAi drugs from Chi­nese biotech for $185M up­front

No­var­tis has inked a pair of li­cense and col­lab­o­ra­tion deals with RNA-fo­cused biotech Shang­hai Ar­go Bio­phar­ma­ceu­ti­cal for two car­dio­vas­cu­lar drugs, in a trans­ac­tion worth $185 mil­lion in up­front pay­ments.

Un­der the terms of the first agree­ment, No­var­tis will get an ex­clu­sive glob­al li­cense for a Phase I as­set and the op­tion to li­cense pro­grams against up to two car­dio­vas­cu­lar tar­gets de­vel­oped un­der a sep­a­rate re­search col­lab­o­ra­tion with Shang­hai Ar­go. The sec­ond agree­ment gives No­var­tis an ex­clu­sive li­cense for a Phase I/IIa pro­gram out­side of Chi­na and oth­er near­by ter­ri­to­ries.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER